Growth arrest-specific gene 6 expression in human breast cancer
Mc Cormack, O
Chung, W Y
Goldrick, A Mc
Dervan, P A
Mc Cann, A
Kerin, M J
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 36 times in Scopus (view citations)
Mc Cormack, O; Chung, W Y; Fitzpatrick, P; Cooke, F; Flynn, B; Harrison, M; Fox, E; Gallagher, E; Goldrick, A Mc; Dervan, P A; Mc Cann, A; Kerin, M J (2008). Growth arrest-specific gene 6 expression in human breast cancer. British Journal of Cancer 98 (6), 1141-1146
Growth arrest- specific gene 6 ( Gas6), identified in 1995, acts as the ligand to the Axl/ Tyro3 family of tyrosine kinase receptors and exerts mitogenic activity when bound to these receptors. Overexpression of the Axl/ Tyro3 receptor family has been found in breast, ovarian and lung tumours. Gas6 is upregulated 23- fold by progesterone acting through the progesterone receptor B ( PRB). Recently, Gas6 has been shown to be a target for overexpression and amplification in breast cancer. Quantitative real- time PCR analysis was used to determine the levels of Gas6 mRNA expression in 49 primary breast carcinomas. Expression of PRB protein was evaluated immunohistochemically with a commercially available PRB antibody. The results showed a positive association between PRB protein and Gas6 mRNA levels ( P =0.04). Gas6 correlated positively with a number of favourable prognostic variables including lymph node negativity ( P =0.0002), younger age at diagnosis ( P =0.04), smaller size of tumours ( P =0.02), low Nottingham prognostic index scores ( P =0.03) and low nuclear morphology ( P =0.03). This study verifies for the first time the association between PRB and Gas6 in breast cancer tissue.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Showing items related by title, author, creator and subject.
The trail-receptor-1: trail-receptor-3 and -4 ratio is a predictor for trail sensitivity of cancer cells Zwacka, (Spandidos Publications, 2009-04-06)The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a ...
Enhancement of estrogen receptor transcriptional activity by the coactivator grip-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology Norris, John D.; Fan, Daju; Stallcup, Michael R.; McDonnell, Donald P. (American Society for Biochemistry & Molecular Biology (ASBMB), 1998-03-20)The human estrogen receptor (ER) contains two major activation functions (AFs) responsible for its transcriptional activity. One of these, activation function 2 (AF-2), located within the hormone-binding domain (HBD), has ...
Dr4 specific trail variants are more efficacious than wild-type trail in pancreatic cancer Yu, Rui; Albarenque, Stella Maris; Cool, Robbert H; Quax, Wim J; Mohr, Andrea; Zwacka, Ralf M (Informa UK Limited, 2014-11-20)Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since ...